Dr. Priya Kishnani, an Informative Session on the Covid 19 Vaccine with Questions and Answers

Speaker Biography

Dr. Priya Kishnani, MD

Chief, Division of Medical Genetics, Department of Pediatrics; Professor of Molecular Genetics and Microbiology, Duke University Medical Center

Dr. Priya Kishnani, MD, is Chief of the Division of Medical Genetics in the Department of Pediatrics, and Professor of Molecular Genetics and Microbiology at Duke University Medical Center. She holds certifications from the American Board of Medical Genetics and the American Board of Biochemical Genetics. She holds numerous appointments at Duke University Medical Center, serving as Director of the Glycogen Storage Disease Clinical and Research Program, Director of Clinical Trials, and Director of the YT and Alice Chen Center for Genomic Research and of the Metabolic Clinic. 

Her passion is to establish the highest quality of care and treatment by understanding the emerging natural history of individuals through investigator-initiated studies and clinical research trials with a focus on glycogen and lysosomal storage disorders. She has published extensively on these conditions, through research publications, textbooks, and scientific reviews. 

Dr. Kishnani was involved in the clinical development of alglucosidase alfa for the treatment of Pompe disease (PD), resulting in its US Food and Drug Administration (FDA) approval in 2006, and in the development of avalglucosidase alfa-ngpt as a second-generation enzyme treatment, which wa approved by the FDA in 2021. She also focuses on next-generation therapies such as gene therapy and other modalities to treat PD. As well as having an interest in long-term complications of PD, Dr. Kishnani and her team at Duke University played an integral role in the nomination and approval for the addition of PD to the Recommended Uniform Screening Panel for newborn screening in the United States in 2015.